PitchBook is launching new coverage of the pharmatech sector, an industry comprising contract organizations and outsourcing services for drug research, development, and manufacturing—CROs, CDMOs, and CMOs for those in the know. Kazi Helal, Ph.D., PitchBook’s Senior Analyst covering biotech, breaks out the market landscape and deal activity across segments in the inaugural report. The sector has traditionally been dominated by a handful of large companies. However, both PE and VC investors are now finding inroads and leveraging the current turbulence of post-pandemic global biomanufacturing needs to syndicate deals in this emerging lucrative space.
Read the full article: PitchBook’s Q1 2024 Launch Report: Pharmatech //
Source: https://pitchbook.com/news/reports/q1-2024-launch-report-pharmatech